Clinical trials
Alzheimer Disease or Associated Disorder clinical trials
Below are recruiting alzheimer disease or associated disorder clinical trials, each written for real people, not researchers. We’re tracking 1,824 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07170150RecruitingPhase 3
A study of trontinemab for early Alzheimer's disease
This trial tests an investigational drug called trontinemab in people with early symptomatic Alzheimer's disease. It aims to see if it can slow down memory and thinking problems.
Phoenix, ArizonaAges 50–90 - NCT07208344RecruitingEarly Phase 1
Umbilical cord blood infusion for Alzheimer's disease
This early-phase study tests whether infusing donated umbilical cord blood (a source of young immune cells) can help slow Alzheimer's disease. It is for people aged 50–75 with mild to moderate Alzheimer's who have a caregiver and are otherwise generally healthy.
Hefei, AnhuiAges 50–75 - NCT07213349RecruitingPhase 2
Daridorexant for Alzheimer's prevention
This study tests whether daridorexant, a medication that helps improve sleep, can prevent Alzheimer's disease. If you have mild memory concerns but not dementia, this trial may help find out if better sleep can protect your brain.
Montreal, QuebecAges 50–90 - NCT07214727RecruitingPhase 1
A study of ALN-5288 for Alzheimer's disease
This trial tests an investigational drug called ALN-5288 for people with Alzheimer's disease. It aims to see if the drug is safe and how it affects the body.
MontrealAges 40–80 - NCT07224607Recruiting
Light therapy for early Alzheimer's disease
This study tests a type of light therapy (called transcranial photobiomodulation) to see if it can help people with early-stage Alzheimer's. It involves coming to Cedars-Sinai for weekly sessions over a period of time.
Los Angeles, CaliforniaAges 55–89 - NCT06194799Enrolling by invitationPhase 3
Long-term ACP-204 for Alzheimer's psychosis
This study tests a long-term medicine (ACP-204) for people with Alzheimer's disease who also have psychosis (hallucinations or delusions). If you took part in the earlier ACP-204 study, this open-label extension lets you continue receiving the medicine to see how well it works over time.
Costa Mesa, CaliforniaAges 55–95 - NCT07294885Recruiting
Lymphatic surgery for Alzheimer's disease
This study tests a surgical procedure to connect lymph vessels in the neck to veins, which may help clear waste from the brain in people with mild cognitive impairment or mild to moderate Alzheimer's disease. It is for patients who have not improved after at least 3 months of standard care.
ShenyangAges 50–80 - NCT07323927RecruitingEarly Phase 1
Testing galcanezumab for Alzheimer's disease
This trial tests whether galcanezumab, an antibody injection, can help people with mild-to-moderate Alzheimer's disease. It is for patients who have a confirmed Alzheimer's diagnosis and a caregiver who can support them.
BeijingAges 50–90 - NCT07332260RecruitingPhase 1
Fecal transplant for Alzheimer's disease
This study tests whether a fecal transplant (transferring healthy bacteria from a donor's stool into your colon) can improve memory and thinking in people with mild to moderate Alzheimer's. You would receive the transplant via colonoscopy and have follow-up brain scans.
Tromsø, TromsAges 18 years+ - NCT07341009Recruiting
Study of time processing skills in Alzheimer's disease
This study uses a brain game to measure how people with Alzheimer's disease process the passage of time. The goal is to better understand this ability, which could lead to new ways to support patients.
CaenAges Any age - NCT07328451RecruitingPhase 1
Study of DNL628 for people with early Alzheimer's disease
This trial tests an experimental drug, DNL628, to see if it is safe and how it affects people with early Alzheimer's disease. It may help slow the disease by targeting a specific process in the brain.
's-HertogenboschAges 18–75 - NCT07367815RecruitingPhase 1/Phase 2
Stem cells from fat tissue for Alzheimer's disease
This trial tests whether stem cells from donated fat tissue can help people with mild to moderate Alzheimer's disease. It combines infusions of these cells with standard care, and includes brain scans and memory tests to see if the treatment is safe and effective.
ToulouseAges 50–85 - NCT02414347Recruiting
Tau PET scan study for Alzheimer’s disease
This study uses a PET brain scan with a small injected tracer to look for “tau” protein changes linked to Alzheimer’s disease. It may help researchers better understand how tau appears in people who are cognitively normal or have mild dementia.
St Louis, MissouriAges 18 years+ - NCT02800395Recruiting
Study links brain changes to diet and blood markers in Alzheimer’s
This study looks at how diet-related and blood “stress” markers relate to how thinking and memory decline over time in people with Alzheimer’s. It may help researchers find useful biomarkers to better track progression and guide future care.
Pierre-BéniteAges 55 years+ - NCT02811653Recruiting
Brain movement and memory study in early dementia
This study looks at how “slower movement” and brain changes relate to memory and thinking problems in people with early dementia (and some related conditions). It may help researchers understand what brain differences go with these symptoms, using tests and an MRI scan.
AmiensAges 40–85 - NCT03035851Recruiting
Exercise program for older adults at risk of memory decline
This trial tests whether a structured aerobic (heart-pumping) exercise program can improve memory and thinking in older adults who feel memory trouble but have not been diagnosed with dementia. It focuses on people who are “at increased risk” due to common health factors like high blood pressure or diabetes.
Calgary, AlbertaAges 50–80 - NCT07496021Recruiting
Probiotic for early Alzheimer's: safety and memory benefits
This trial tests a new probiotic (Lactococcus lactis CKDB001) to see if it can slow memory loss in people with early Alzheimer's. It’s a 12-week study that requires a positive amyloid PET scan and allows mild to moderate symptoms.
Gyeonggi-doAges 55–85 - NCT07512362RecruitingPhase 2
Stem cells and antibodies for early Alzheimer's disease
This study tests whether human stem cells, combined with your existing Alzheimer's medication (Leqembi or Kisunla), can help slow memory loss and improve daily functioning in people with mild cognitive impairment or early Alzheimer's. You would receive a stem cell infusion as an add-on to your current treatment.
Miami, FloridaAges 55–90 - NCT07570719Recruiting
Community screening for early Alzheimer's disease signs
This study screens people aged 60–80 for early signs of Alzheimer's disease in a community setting. Researchers will ask you questions and may perform brain imaging to understand who might benefit from early detection and treatment.
Shanghai, Shanghai MunicipalityAges 60–80 - NCT07571161RecruitingPhase 3
Donanemab for early Alzheimer's disease in Chinese participants
This trial tests a drug called donanemab in people who have early signs of Alzheimer's disease (amyloid buildup in the brain) but are still thinking clearly. The goal is to see if the drug can slow or prevent cognitive decline before memory problems start.
BeijingAges 55–80 - NCT07598617Recruiting
Testing a New Computer Memory Assessment for Early Cognitive Changes
This study evaluates a new computer-based test to detect early memory and thinking changes before they progress to dementia. Researchers are looking for adults 65+ who've noticed subtle cognitive changes in the last 5 years to help refine and test this assessment tool.
Plymouth, DevonAges 65 years+ - NCT07599670RecruitingPhase 1/Phase 2
Safety study of ABBV-1758 injection for Alzheimer's disease
This early-stage trial tests whether ABBV-1758, a new drug given by injection, is safe and effective for people with Alzheimer's disease. The drug targets amyloid, a protein that builds up in the brains of people with Alzheimer's.
Irvine, CaliforniaAges 50–90 - NCT07600996Recruiting
Brain Fluid Markers in Stroke and Alzheimer's Disease
This study examines special proteins in cerebrospinal fluid (the fluid around your brain and spinal cord) to better understand ischemic stroke and Alzheimer's disease. Researchers hope these markers will help predict outcomes and guide future treatments.
Beijing, None SelectedAges 18 years+ - NCT07666113Recruiting
Blood test for Alzheimer's disease detection in primary care
This study tests whether a simple blood test can help detect Alzheimer's disease in people who visit their primary care doctor with memory concerns. It aims to improve early diagnosis at the community level.
LeuvenAges 55–85
Hear when a new Alzheimer Disease or Associated Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer disease or associated disorder?
- Yes. Clin2 currently lists 1,824 recruiting alzheimer disease or associated disorder studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer disease or associated disorder trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer disease or associated disorder trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.